This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: The treatment of individuals infected with hepatitis B virus (HBV) is a complex issue in practical settings, despite the explosion of new and effective antiviral agents. OBJECTIVE: To assess the scope and limitations of ongoing treatment guidelines against HBV from a global perspective. METHODS: Present therapeutic guidelines against HBV have been discussed with emphasis on their value in developing countries that harbor about 90% of the total number of global patients who are infected with HBV. RESULTS/CONCLUSION: Treatment of HBV-infected patients should be appropriately followed up and healthcare delivery systems should be able to combat treatment-induced adverse side effects. Current therapeutic guidelines should be optimized based on the socio-economic conditions of developing countries.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Akbar et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: